Meta­bol­ic dis­ease out­fit ac­cus­es Chi­nese biotech of steal­ing trade se­crets to ad­vance com­pet­ing drug

NASH is a big in­di­ca­tion with plen­ty of ben­e­fits to the first com­pa­ny that can suc­cess­ful­ly get a work­ing drug on the mar­ket. And ac­cord­ing to one US biotech, a Chi­nese com­pa­ny stole trade se­crets in or­der to get a head start.

Viking Ther­a­peu­tics is su­ing Chi­nese biotech As­cle­tis Phar­ma in Cal­i­for­nia dis­trict court, claim­ing that As­cle­tis es­sen­tial­ly duped the biotech in­to di­vulging its trade se­crets to the com­pa­ny and gave As­cle­tis the op­por­tu­ni­ty to re­lease its own drug prod­uct to di­rect­ly com­pete with Viking.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER